A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF OPERA® FOR REDUCING TREATMENT DISCONTINUATION IN RESECTED COLORECTAL CANCER RECEIVING OXALIPLATIN-BASED ADJUVANT CHEMOTHERAPY
di Prof. S. Cascinu – Division of Oncology, University Hospital of Modena
Primary: To evaluate the efficacy of Opera® in preventing oxaliplatin dose reductions, cycles delays and patient withdraw in patients receiving oxaliplatin-containing adjuvant chemotherapy for resected colorectal cancer
Secondary: To evaluate the impact of Opera® on treatment efficacy.
Sottoposto al comitato etico.